Vivoryon Therapeutics NV (FRA:05Y) EV-to-Revenue : 1.98 (As of May. 21, 2024)

Vivoryon Therapeutics NV EV-to-Revenue Chart

Vivoryon Therapeutics NV Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-Revenue		Get a 7-Day Free Trial					-	-	34.05	-	-50.73

Vivoryon Therapeutics NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															34.05	-	-	-	-50.73

Competitive Comparison of Vivoryon Therapeutics NV's EV-to-Revenue

For the Biotechnology subindustry, Vivoryon Therapeutics NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's EV-to-Revenue falls into.

Vivoryon Therapeutics NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vivoryon Therapeutics NV's EV-to-Revenue for today is calculated as:

Vivoryon Therapeutics NV's current Enterprise Value is €-7.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV  (FRA:05Y) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vivoryon Therapeutics NV's PS Ratiofor today is calculated as:

Vivoryon Therapeutics NV's share price for today is €0.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €-0.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV (FRA:05Y) Business Description